[Lumiracoxib reduces ulcer complications in comparison to NSAR].
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D001241:Aspirin / Q000009:adverse effects; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D004008:Diclofenac / Q000031:analogs & derivatives; D006801:Humans; D009930:Organic Chemicals / Q000009:adverse effects / Q000627:therapeutic use*; D010003:Osteoarthritis / Q000188:drug therapy; D010437:Peptic Ulcer / Q000139:chemically induced / Q000517:prevention & control*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D009930:Organic Chemicals; D004008:Diclofenac; D001241:Aspirin; C473384:lumiracoxib